CN103119055A - 聚乙二醇化c肽 - Google Patents

聚乙二醇化c肽 Download PDF

Info

Publication number
CN103119055A
CN103119055A CN2011800350917A CN201180035091A CN103119055A CN 103119055 A CN103119055 A CN 103119055A CN 2011800350917 A CN2011800350917 A CN 2011800350917A CN 201180035091 A CN201180035091 A CN 201180035091A CN 103119055 A CN103119055 A CN 103119055A
Authority
CN
China
Prior art keywords
peptide
pegylation
insulin
patient
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800350917A
Other languages
English (en)
Chinese (zh)
Inventor
雪莉·巴瑞克
詹姆斯·考拉维
密雪儿·玛佐尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cebix Inc
Original Assignee
Cebix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cebix Inc filed Critical Cebix Inc
Publication of CN103119055A publication Critical patent/CN103119055A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
CN2011800350917A 2010-05-17 2011-05-17 聚乙二醇化c肽 Pending CN103119055A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34529310P 2010-05-17 2010-05-17
US61/345,293 2010-05-17
US201161448402P 2011-03-02 2011-03-02
US61/448,402 2011-03-02
PCT/US2011/036858 WO2011146518A2 (en) 2010-05-17 2011-05-17 Pegylated c-peptide

Publications (1)

Publication Number Publication Date
CN103119055A true CN103119055A (zh) 2013-05-22

Family

ID=44992295

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800350917A Pending CN103119055A (zh) 2010-05-17 2011-05-17 聚乙二醇化c肽

Country Status (9)

Country Link
US (2) US8927488B2 (https=)
EP (1) EP2571896A4 (https=)
JP (1) JP2013533217A (https=)
KR (1) KR20130115086A (https=)
CN (1) CN103119055A (https=)
CA (1) CA2798518A1 (https=)
MX (1) MX2012013375A (https=)
NZ (1) NZ603399A (https=)
WO (1) WO2011146518A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849108A (zh) * 2015-03-03 2018-03-27 阿瓦隆生物制品有限公司 聚乙二醇化的il‑11的组合物和方法
CN108026182A (zh) * 2015-09-18 2018-05-11 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
CN108265044A (zh) * 2016-12-31 2018-07-10 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN114137094A (zh) * 2020-09-03 2022-03-04 北京渼颜空间生物医药有限公司 一种聚左旋乳酸中有关物质的检测方法

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP2552967A4 (en) * 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
CA2798518A1 (en) 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
EP2755675B1 (en) * 2011-09-12 2018-06-06 Amunix Operating Inc. Glucagon-like peptide-2 compositions and methods of making and using same
US8962553B2 (en) 2011-11-17 2015-02-24 Cebix Ab Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
US20130288973A1 (en) * 2011-12-14 2013-10-31 Edmund Burke Decellularized small particle tissue
US9988433B2 (en) * 2013-03-14 2018-06-05 Mosaic Biosciences, Inc. Covalent modification of biological macromolecules
WO2013116791A1 (en) 2012-02-02 2013-08-08 Mosaic Biosciences, Inc. Biomaterials for delivery of blood extracts and methods of using same
US20150087586A1 (en) * 2012-03-29 2015-03-26 Cebix, Inc. Pegylated c-peptide
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
MX375448B (es) * 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
RU2733495C2 (ru) * 2013-09-24 2020-10-02 Аллерган Фармасьютикалз Интернэшнл Лимитед Способ экстракции белка
RU2017131285A (ru) * 2015-02-09 2019-03-11 Мозеик Байосайенсиз, Инк. Биоразлагаемые тиол-ен-полимеры и способы их получения
CA2979397A1 (en) 2015-03-12 2016-09-15 Board Of Trustees Of Michigan State University Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases
BR112019026711A2 (pt) 2017-06-16 2020-06-30 Zealand Pharma A/S regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2)
JP7058857B2 (ja) * 2017-08-30 2022-04-25 クラシエホームプロダクツ株式会社 毛髪タンパク質の水との相互作用測定方法
EP3449935A1 (en) * 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
WO2019067676A1 (en) * 2017-09-28 2019-04-04 The Regents Of The University Of California HYDROGELS OF POLYIONIC POLYPEPTIDE COMPLEXES AND USES THEREOF
US11357861B2 (en) 2017-09-29 2022-06-14 Hanmi Pharm. Co., Ltd Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor
CA3084013A1 (en) 2017-12-01 2019-06-06 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
PT3716998T (pt) * 2017-12-01 2024-04-09 Csl Behring Llc A1at para reduzir risco de início de doença do enxerto contra hospedeiro aguda após transplante de células hematopoiéticas
SI3793586T1 (sl) * 2018-05-16 2024-07-31 Csl Limited Različice receptorja za topni komplement tipa 1 in njihova uporaba
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628682A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
WO2020085506A1 (ja) * 2018-10-25 2020-04-30 国立大学法人大阪大学 軟骨疾患の治療薬
BR112021008098A2 (pt) 2018-11-15 2021-08-10 Quantum-Si Incorporated métodos e composições para o sequenciamento de proteínas
US20220177704A1 (en) * 2019-03-27 2022-06-09 The Regents Of Theuniversity Of California Mixtures of synthetic copolypeptide hydrogels
US12390534B2 (en) 2019-03-29 2025-08-19 Nof Corporation Branched degradable polyethylene glycol binder
EP3950776A4 (en) * 2019-03-29 2023-01-04 NOF Corporation BRANCHED AND DEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE
CN111939244B (zh) * 2019-05-14 2024-08-06 阿莫生命科学有限公司 用于预防或治疗糖尿病并发症的药物组合物
KR102456958B1 (ko) 2019-05-14 2022-10-21 강원대학교 산학협력단 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물
EP4147711A4 (en) * 2020-04-20 2024-04-24 Shionogi & Co., Ltd FORMULATION WITH A HMGB1 PARTIAL PEPTIDE
US12090206B2 (en) 2020-04-23 2024-09-17 The Regents Of The University Of California Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels
WO2021236983A2 (en) * 2020-05-20 2021-11-25 Quantum-Si Incorporated Methods and compositions for protein sequencing
WO2022119563A1 (en) * 2020-12-02 2022-06-09 Shih Chun Che Composition and method for treatment of ischemic disease
US20220401525A1 (en) * 2021-06-16 2022-12-22 Biocell Technology, Llc Use of collagen compositions for increasing telomere length
CN116554267A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 聚乙二醇修饰的激肽或其变体和药物应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022210A2 (en) * 2001-09-07 2003-03-20 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
US20030228275A1 (en) * 2001-06-04 2003-12-11 Ekwuribe Nnochiri N. Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2005118638A1 (en) * 2004-06-01 2005-12-15 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
WO2006097521A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
CN101573133A (zh) * 2006-07-31 2009-11-04 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
WO2010033207A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2010033204A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of c-peptides

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH650679A5 (de) * 1981-08-27 1985-08-15 Lilly Co Eli Gegen diabetes mellitus wirksames pharmazeutisches mittel.
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
FR2686759B1 (fr) 1992-01-29 1994-04-22 Sgs Thomson Microelectronics Dispositif de regulation de puissance pour un haut-parleur de poste de telephone pendant une sonnerie .
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
GB9716790D0 (en) 1997-08-07 1997-10-15 Creative Peptides Sweden Ab Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
NZ512663A (en) * 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
ES2333781T3 (es) 2001-09-07 2010-03-01 Biocon Limited Procedimientos de sintesis de conjugados de polipeptido insulina-oligomero y conjugados de polipeptido proinsulina-oligomero, y procedimientos de sintesis de los mismos.
AU2002352524B2 (en) * 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
AP2004003050A0 (en) * 2001-11-20 2004-06-30 Pharmacia Corp Chemically modified human growth hormone conjugates
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
NZ540490A (en) 2002-09-09 2007-10-26 Nektar Therapeutics Al Corp Water-soluble polymer alkanal conjugates with human growth hormone
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
WO2004060965A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
TR201907313T4 (tr) 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
US20050074425A1 (en) 2003-07-02 2005-04-07 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
ES2629696T3 (es) * 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
PL1745062T3 (pl) * 2004-04-22 2014-10-31 Regado Biosciences Inc Ulepszone modulatory czynników krzepnięcia
WO2005107815A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Polymer derivatives comprising an imide branching point
US8562965B2 (en) 2004-05-03 2013-10-22 Nektar Therapeutics Polymer derivatives comprising an acetal or ketal branching point
EP1850878A2 (en) * 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP2412744B1 (en) 2005-07-18 2014-01-22 Nektar Therapeutics Method for preparing branched functionalised polymers using branched polyol cores
GB0601950D0 (en) 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
JP4261531B2 (ja) 2005-09-06 2009-04-30 株式会社Ｎｒｌファーマ ラクトフェリン複合体及びその製造方法
WO2008012528A1 (en) * 2006-07-25 2008-01-31 Lipoxen Technologies Limited N-terminal polysialylation
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
RU2007137048A (ru) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство для лечения и предупреждения осложнений при сахарном диабете
US20110182946A1 (en) 2008-03-17 2011-07-28 Board Of Regents, The University Of Texas System Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
WO2011081915A2 (en) 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
CA2798518A1 (en) 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228275A1 (en) * 2001-06-04 2003-12-11 Ekwuribe Nnochiri N. Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003022210A2 (en) * 2001-09-07 2003-03-20 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
WO2005118638A1 (en) * 2004-06-01 2005-12-15 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
WO2006097521A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
CN101573133A (zh) * 2006-07-31 2009-11-04 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
WO2010033207A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2010033204A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of c-peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吴浩等: "蛋白质药物的聚乙二醇修饰", 《药学进展》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849108A (zh) * 2015-03-03 2018-03-27 阿瓦隆生物制品有限公司 聚乙二醇化的il‑11的组合物和方法
CN108026182A (zh) * 2015-09-18 2018-05-11 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
CN108265044A (zh) * 2016-12-31 2018-07-10 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN114137094A (zh) * 2020-09-03 2022-03-04 北京渼颜空间生物医药有限公司 一种聚左旋乳酸中有关物质的检测方法

Also Published As

Publication number Publication date
WO2011146518A9 (en) 2012-04-19
WO2011146518A2 (en) 2011-11-24
EP2571896A4 (en) 2014-01-08
EP2571896A2 (en) 2013-03-27
US8691755B2 (en) 2014-04-08
NZ603399A (en) 2014-09-26
MX2012013375A (es) 2013-04-11
KR20130115086A (ko) 2013-10-21
US20120178676A1 (en) 2012-07-12
US8927488B2 (en) 2015-01-06
US20120220542A1 (en) 2012-08-30
CA2798518A1 (en) 2011-11-24
WO2011146518A3 (en) 2012-03-08
JP2013533217A (ja) 2013-08-22

Similar Documents

Publication Publication Date Title
CN103119055A (zh) 聚乙二醇化c肽
US20110009314A1 (en) Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
US7524940B2 (en) OB protein compositions and methods
CN101194016A (zh) 尿酸氧化酶的变体形式及其用途
CN102321170B (zh) 利拉鲁肽变构体及其缀合物
EP2894163A1 (en) A glp-1 analogue, its preparation methods and use thereof
CN102634492A (zh) 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
US20020107175A1 (en) Insulin c-peptides
CA2710841C (en) Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof
US8962553B2 (en) Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
US20150087586A1 (en) Pegylated c-peptide
AU2003284428B2 (en) Peptides and medicinal compositions containing the same
CN119912526A (zh) 一种具有增肌功能的七肽及其制备和应用
KR20010006392A (ko) 안정한 활성 인체 ｏｂ 단백질 및 항체 ｆｃ 사슬 복합체를 함유하는 조성물 및 방법
CN113121649B (zh) 一种新型两亲性蛋白、其制备方法及用途
EP1915179A2 (en) Human growth hormone conjugated with biocompatible polymer
CN104447981B (zh) 端羟基聚乙二醇化的人胰岛素及其类似物的偶联物
US20060134736A1 (en) Human growth hormone conjugated with biocompatible polymer
AU2011256203A1 (en) PEGylated C-peptide
WO2025098422A1 (zh) 多重受体共激动剂化合物及其制备方法与应用
AU4866700A (en) OB protein compositions and method
RU98104123A (ru) Химические соединения

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130522